Core Insights - CAMP4 Therapeutics has entered a strategic collaboration with GSK to develop antisense oligonucleotide (ASO) drug candidates targeting neurodegenerative and kidney diseases, leveraging CAMP4's RAP Platform [1][4][5] Financial Terms - CAMP4 will receive an upfront payment of $17.5 million and is eligible for additional milestone-based payments and tiered royalties on future product sales [3][1] Collaboration Details - The collaboration aims to identify and develop ASO candidates that increase the expression of validated genetic targets, addressing the critical role of protein under-expression in diseases [2][5] - GSK will handle the further development and commercialization of the ASO drug candidates identified through this partnership [4] Technology and Approach - CAMP4's RAP Platform is designed to identify regulatory RNAs (regRNAs) that control gene expression, enabling the generation of ASO candidates that amplify target gene expression [4][6] - The company focuses on amplifying mRNA to develop disease-modifying treatments for over 1,200 genetic diseases where increased protein expression may provide therapeutic benefits [6]

Core Insights - CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics aimed at treating genetic diseases by restoring healthy protein levels [1][3] Group 1: Inducement Grants - On December 11, 2025, the Board of Directors granted non-qualified stock options to purchase a total of 92,000 shares to four newly hired employees as an inducement for their employment [1] - The options have a ten-year term with an exercise price of $6.01, equal to the closing price on the Grant Date [2] - The options will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on continued service [2] Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases where increasing healthy protein levels may provide therapeutic benefits [3] - The company's approach involves amplifying mRNA by targeting regulatory RNAs (regRNAs), which are crucial for gene expression control [3] - CAMP4's proprietary RAP Platform® is designed to map regRNAs and create therapeutic candidates targeting those associated with haploinsufficient and recessive partial loss-of-function disorders [3]